Sarcopenia predicts prognosis of patients with renal cell carcinoma: A systematic review and meta-analysis

Hu, Xu; Liao, Du-Wu; Yang, Zhiqiang; Yang, Weixiao; Xiong, San-Chao; Li, Xiang

doi:10.1590/s1677-5538.ibju.2019.0636

Cited by 23 publications

(28 citation statements)

References 42 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with gastric cancer, sarcopenia was associated with mortality, postoperative complications, hospital costs, and postoperative hospital stay [ 26 ]. In renal cell carcinoma and urogenital tumors, patients with sarcopenia showed reduced overall survival and cancer-specific survival compared to patients without sarcopenia [ 27 28 ]. Sarcopenia is associated with a reduction in overall and recurrence-free survival in head and neck cancer [ 29 ].…”

Section: Sarcopeniamentioning

confidence: 99%

Rehabilitation Nutrition and Exercise Therapy for Sarcopenia

Kakehi

Wakabayashi

Inuma

et al. 2022

World J Mens Health

View full text Add to dashboard Cite

Sarcopenia is an age-related loss of skeletal muscle associated with adverse outcomes such as falls, fractures, disability, and increased mortality in older people and hospitalized patients. About half of older male nursing home residents have sarcopenia. The diagnostic criteria by the European Working Group on Sarcopenia in Older People (EWGSOP) and the Asian Working Group for Sarcopenia (AWGS) have led to increased interest in sarcopenia. Exercise and nutritional management are crucial for the prevention and treatment of sarcopenia. Nutritional therapy for sarcopenia that includes 20 g of whey protein and 800 IU of vitamin D twice a day improves lower limb strength. Exercise therapy for sarcopenia, such as resistance training and 6 months of home exercises, improves muscle strength and physical function. Combination therapy that includes both nutritional and exercise therapy improves gait speed and knee extension strength more than either exercise alone or nutrition therapy alone. Excessive bedrest and mismanagement of nutrition in medical facilities can lead to iatrogenic sarcopenia. Iatrogenic sarcopenia is sarcopenia caused by the activities of health care workers in health care facilities. Appropriate nutritional management and exercise programs through rehabilitation nutrition are important for prevention and treatment of iatrogenic sarcopenia. Nutritional and exercise therapy should be started very early after admission and adjusted to the level of inflammation and disease status. Repeated assessment, diagnosis, goal setting, interventions, and monitoring using the rehabilitation nutrition care process is important to maximize treatment effectiveness and improve patients' functional recovery and quality of life.

show abstract

Section: Sarcopeniamentioning

confidence: 99%

Rehabilitation Nutrition and Exercise Therapy for Sarcopenia

Kakehi

Wakabayashi

Inuma

et al. 2022

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…The most common type of kidney originating cancer is renal cell carcinoma (RCC) [ 1 ]. When initially diagnosed, bout 70% of patients with RCC have localized diseases and the remaining 30% are at regional metastatic and distant metastatic status [ 3 ]. Although most patients with RCC at localized stages are treated by surgical resection, RCC remains one of the most lethal urological malignancies [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic impact of prognostic nutritional index on renal cell carcinoma: A meta-analysis of 7,629 patients

Peng

Liu

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Background Prognostic nutritional index (PNI) is a parameter which reflects nutritional and inflammatory status. The prognostic value of PNI in renal cell carcinoma (RCC) remains in debate. The aim of this study is to evaluate the prognostic value and clinicopathological features of PNI in RCC. Methods A literature search was performed in the databases of PubMed, Embase, Web of Science, and Cochrane Library. Hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were extracted for meta-analysis. The association between PNI and overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), progression-free survival (PFS), recurrence-free survival (RFS), and clinicopathological factors were evaluated. Results Eleven studies involving 7,629 patients were included for meta-analysis. A decreased PNI was shown to be a significant predictor of worse OS (HR = 2.00, 95%CI = 1.64–2.42, p<0.001), CSS (HR = 2.54, 95%CI = 1.61–4.00, p<0.001), and DFS/PFS/RFS (HR = 2.12, 95%CI = 1.82–2.46, p<0.001) in RCC. Furthermore, a low PNI was correlated with Fuhrman grade III-IV (OR = 1.96, 95%CI = 1.27–3.02, p = 0.002), T stage T3-T4 (OR = 2.21, 95%CI = 1.27–3.87, p = 0.005), presence of sarcomatoid differentiation (OR = 5.00, 95%CI = 2.52–9.92, p<0.001), and presence of tumor necrosis (OR = 3.63, 95%CI = 2.54–5.19, p<0.001). Conclusion PNI is an independent prognostic indicator of survival and associated with Fuhrman grade, T stage, sarcomatoid differentiation, and tumor necrosis in patients with RCC.

show abstract

“…Sarcopenia occurs in approximately 50% of advanced cancer patients, being related to malnutrition, inflammation and tumor treatments [ 6 ]. In these patients, it has been demonstrated to be associated with worse outcomes in terms of overall survival (OS) and progression free survival (PFS), and it can be considered as a negative prognostic factor for different types of cancer, regardless of stage or treatment approach [ 7 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study

Tenuta

Pandozzi

Sirgiovanni

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Sarcopenia is a condition characterized by loss of skeletal muscle mass associated with worse clinical outcomes in cancer patients. Data on sarcopenia in patients undergoing immune checkpoint inhibitors (ICI) therapy are still limited. The aim of this prospective observational study was to investigate the relationship between sarcopenia, ICI treatment response and immunological profile, in patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-seven stage IV NSCLC patient candidates for starting ICI, were enrolled from the Policlinico Umberto I outpatient Oncology. Patients underwent baseline blood test, inflammatory markers, cytokine assessment and body composition with dual-energy X-ray absorptiometry (DXA). Sarcopenia was defined with appendicular skeletal muscle mass over height2 (ASM/heigh2). Results: Overall, 19/47 patients (40.4%) results were sarcopenic. Sarcopenic patients showed significantly shorter PFS than non-sarcopenic ones (20.3 weeks, 95% CI 7.5–33.1 vs. 61 weeks, 95% CI 22.5–99.4, p = 0.047). Specifically, they had an 8.1 times higher risk of progression disease (PD) than non-sarcopenic patients (OR 8.1, 95%, p = 0.011). Conclusions: Sarcopenic patients showed worse PFS and had a higher risk of PD compared to non-sarcopenic ones. Therefore, sarcopenia may reflect the increased metabolic activity of more aggressive tumors, which involves systemic inflammation and muscle wasting and could be considered a negative predictive factor for ICI response.

show abstract

Sarcopenia predicts prognosis of patients with renal cell carcinoma: A systematic review and meta-analysis

Cited by 23 publications

References 42 publications

Rehabilitation Nutrition and Exercise Therapy for Sarcopenia

Rehabilitation Nutrition and Exercise Therapy for Sarcopenia

Prognostic impact of prognostic nutritional index on renal cell carcinoma: A meta-analysis of 7,629 patients

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study

Contact Info

Product

Resources

About